A Clearer Future Down Under? New Eye Drops Aim to Replace Reading Glasses

SAN DIEGO, CA & MELBOURNE, AU – June 24, 2026 – For millions of people over 45, the daily ritual of reaching for reading glasses is an unavoidable sign of aging. But a new partnership announced today aims to disrupt that inevitability, promising a future where clear near vision could be just an eye drop away. US-based LENZ Therapeutics has signed an exclusive agreement with Arrotex Pharmaceuticals, Australia's largest pharmaceutical company, to bring its novel presbyopia treatment, VIZZ™, to Australia and New Zealand.

The deal provides Arrotex with the exclusive rights to register and commercialize the vision-restoring drops, marking a significant step in making this technology accessible outside the United States. For the vast number of people in the region experiencing the frustrating, age-related blur of presbyopia, this news signals the potential end of a decades-long reliance on corrective lenses.

A New Vision for an Age-Old Problem

Presbyopia is the inevitable, gradual loss of near vision that affects nearly everyone starting in their mid-40s. As the eye's natural lens hardens with age, its ability to focus on close objects diminishes, making simple tasks like reading a text message, a menu, or a book without assistance a daily struggle. The Australian eye care market, valued at over a billion dollars, has traditionally addressed this with reading glasses, bifocals, or multifocal contact lenses.

VIZZ™ (aceclidine ophthalmic solution) 1.44% represents a paradigm shift. As the first and only FDA-approved eye drop based on the active ingredient aceclidine, it offers a pharmacological alternative. The once-daily, preservative-free drop works through a mechanism known as pupil-selective miosis. It gently constricts the pupil to create a “pinhole effect,” which increases the depth of focus and allows the eye to see near objects clearly without significantly engaging the eye's focusing muscle. This targeted action is a key differentiator from earlier-generation presbyopia drops, which can sometimes cause unwanted side effects like headaches or difficulty seeing in dim light.

Clinical trial data is promising. VIZZ demonstrated a rapid onset, improving near vision within 30 minutes for many participants, with effects lasting up to 10 hours. “We are pleased to expand our global commercial partnership network for VIZZ into Australia and New Zealand,” said Eef Schimmelpennink, President and CEO of LENZ Therapeutics, in a statement. He emphasized that the partnership underscores a commitment to “broadening access to our transformative presbyopia therapy worldwide.”

The Strategy Behind a Global Rollout

The agreement with Arrotex is a critical piece of LENZ Therapeutics' broader international strategy. It is the fifth ex-US commercialization partnership for VIZZ, following its FDA approval in July 2025 and its US market launch in October 2025. For LENZ, these international deals are vital for building revenue streams and establishing VIZZ as a global standard of care.

While the company reported initial VIZZ product sales of $1.7 million in the first quarter of 2026, its stock performance has been challenging, with some analysts citing a slower-than-expected sales trajectory in the competitive US market. This makes the success of its global expansion paramount. The financial terms of the Arrotex deal, which include an upfront payment and a “significant profit share” of gross margin for LENZ, highlight the potential upside. Securing a strong foothold in a developed market like Australia and New Zealand is a strategic move to demonstrate growth and validate the product's commercial potential on a world stage.

This move is particularly timely, as the primary competitor in the presbyopia drop category, Vuity, is not currently available in Australia. This presents VIZZ with a first-to-market opportunity to define the pharmacological treatment landscape for presbyopia in the region.

Arrotex's Home-Field Advantage

For an innovative product to succeed, a powerful local partner is often essential. In choosing Arrotex Pharmaceuticals, LENZ has aligned with a dominant force in the region's healthcare ecosystem. As Australia’s largest and most diversified pharmaceutical company, Arrotex, part of the DBG Health group, brings an “unmatched network of pharmacy partnerships and strong track record of bringing innovative branded medicines to patients,” according to Schimmelpennink.

This deep market penetration and logistical expertise will be crucial for a successful launch. Arrotex’s role will extend beyond simple distribution; it will spearhead the entire commercialization process, from navigating the regulatory pathway to educating healthcare providers and marketing directly to a public eager for alternatives to glasses.

“We are thrilled to bring this innovative therapy to Australia and New Zealand for the treatment of presbyopia to the millions of adults frustrated with their near vision,” said Dennis Bastas, Chairman and Group CEO of DBG Health. He framed VIZZ as a treatment that offers “the potential for greater visual independence and improved quality of life,” aligning with the people-first mission that drives modern healthcare innovation.

Navigating the Path to Patient Access

Despite the excitement surrounding the announcement, patients will need to wait a bit longer to see VIZZ on pharmacy shelves. The agreement grants Arrotex the right to register the product, meaning it must first secure approval from Australia’s Therapeutic Goods Administration (TGA) and New Zealand’s Medsafe.

However, the process may be streamlined. Given VIZZ’s prior FDA approval, Arrotex can likely utilize a “Comparable Overseas Regulator” pathway, which allows local regulators to leverage the assessment of trusted international bodies to expedite their own review. The target timeframe for such a review can be significantly shorter than a full evaluation from scratch, potentially ranging from 120 to 175 working days once the application is accepted.

The submission will be supported by a robust data package from VIZZ's three Phase 3 CLARITY trials, which demonstrated both its efficacy and a favorable safety profile. The most common side effects reported were mild and transient, including temporary instillation-site discomfort and mild dimness of vision. As regulators in Australia and New Zealand begin their evaluation, millions will be watching, hopeful that a life less dependent on reading glasses is just on the horizon.